ALK-Abelló Dirección
Dirección controles de criterios 4/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Peter Halling
Chief Executive Officer (CEO)
DKK 20.6m
Compensación total
| Porcentaje del salario del CEO | 38.19% |
| Permanencia del CEO | 3.6yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 5.6yrs |
| Promedio de permanencia en la Junta Directiva | 6.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Jul 10
ALK B: Allergy Immunotherapy Leadership Will Drive Future Earnings Reassessment
Analysts have raised their price target on ALK-Abelló from DKK 185 to DKK 285, citing the company's position as a global leader in allergy immunotherapy and recent Street research that supports this view. What’s in the News for ALK-Abelló MHRA in the UK granted marketing authorisation for EURneffy 1 mg, the first needle-free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 kg to less than 30 kg.
Actualización de narrativa • Jun 26
ALK B: Paediatric Allergy Approvals Will Drive Future Immunotherapy Leadership
Analysts have raised their price target on ALK-Abelló from DKK 243 to DKK 305, citing the company's position as a global leader in allergy immunotherapy as a key factor in their updated view. What’s in the News for ALK-Abelló UK regulator MHRA granted marketing authorisation for EURneffy 1 mg, the first needle free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 to less than 30 kg, expanding ALK-Abelló’s emergency allergy treatment options in the UK.
Actualización de narrativa • Jun 12
ALK B: Future Returns Will Reflect Allergy Immunotherapy And Anaphylaxis Treatment Progress
Narrative Update on ALK-Abelló The analyst price target for ALK-Abelló has been updated to DKK 305, with analysts pointing to the company’s position as a global market leader in allergy immunotherapy as a key factor in this valuation. What's in the News At the 2026 EAACI Congress, ALK presented data on real world anaphylaxis management, highlighting frequent gaps in adrenaline auto injector use.Actualización de narrativa • May 29
ALK B: Future Upside Will Come From Allergy Immunotherapy Leadership
Analysts have lifted their price target on ALK-Abelló from DKK 263.33 to DKK 297.50, citing the company’s position as a global leader in allergy immunotherapy and recent supportive research coverage. Analyst Commentary Analysts setting a DKK 305 price target frame ALK-Abelló as a global leader in allergy immunotherapy, and they use that positioning to support a constructive view on the stock’s long term potential.Actualización de narrativa • Apr 24
ALK B: Future Upside Will Come From Needle Free Anaphylaxis Treatment Adoption
Analysts have nudged their price target for ALK-Abelló to DKK 263.33 from DKK 255, reflecting updated assumptions around slightly adjusted revenue growth, profit margin expectations, and a higher future P/E multiple. What's in the News ALK reported positive topline phase 2 data from the ALLIANCE trial of its once daily sublingual immunotherapy tablet for peanut allergy in patients aged 4 to 65 years, with statistically significant, dose dependent efficacy across multiple tolerated dose and eliciting dose endpoints and a safety profile without treatment related anaphylaxis or serious adverse events (Key Developments).Actualización de narrativa • Apr 09
ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption
Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.Actualización de narrativa • Mar 25
ALK B: Future Upside Will Rely On Wider Anaphylaxis Spray Adoption
Analysts have kept their DKK price target for ALK-Abelló broadly unchanged at DKK 255, reflecting stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This signals a steady view on the company’s outlook.Actualización de narrativa • Mar 11
ALK B: Future Upside Will Rely On Wider Anaphylaxis Treatment Adoption
Analysts have kept their DKK 255.00 price target for ALK-Abelló unchanged, indicating that their views on fair value, discount rate, expected revenue growth, profit margin and future P/E assumptions remain broadly steady. What's in the News ALK-Abelló presented late-breaking data from a 90-participant study comparing needle-free EURneffy nasal adrenaline to injectable auto-injectors for anaphylaxis, with 88% of participants preferring EURneffy, mainly for ease of use, portability and the absence of a needle (AAAAI 2026 Annual Meeting).Actualización de narrativa • Feb 25
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins
Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).Actualización de narrativa • Feb 10
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Reach And Higher 2025 Margins
Analysts have lifted their fair value estimate for ALK-Abelló from DKK 214 to DKK 249, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending EU marketing authorisation for EURneffy 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older weighing 15 kg to 30 kg.Actualización de narrativa • Jan 27
ALK B: Future Returns Will Reflect Upgraded 2025 Outlook And Stable Margin Ambitions
Analysts have kept their price target for ALK-Abelló steady at DKK 214. This reflects unchanged assumptions around discount rate, revenue growth, profit margin and future P/E, and indicates that new research has not materially shifted their valuation view.Nueva narrativa • Jan 23
Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity
Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?Artículo de análisis • Jan 23
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Actualización de narrativa • Jan 12
ALK B: Future Returns Will Reflect Upgraded Outlook And Balanced Margin Prospects
Analysts have trimmed their price target for ALK-Abelló to €214.00 from €219.33, citing updated assumptions that now reflect slightly higher revenue growth, a modestly lower profit margin outlook and a small adjustment to the projected future P/E multiple. What's in the News ALK-Abelló upgraded its earnings guidance for the full year 2025, with expected revenue growth of 13% to 15% in local currencies, compared with a previous range of 12% to 14% (Key Developments).Actualización de narrativa • Dec 19
ALK B: Future Returns Will Reflect Upgraded Outlook And Solid Margin Prospects
Analysts have modestly lifted their average price target on ALK-Abelló to DKK 219.33, reflecting steady confidence in the company’s unchanged long term growth, margin, and valuation assumptions despite minimal adjustments to underlying model inputs. What's in the News Upgraded 2025 revenue guidance to 13% to 15% growth in local currencies, from 12% to 14%, supported by stronger demand across all regions and product lines (company guidance).Artículo de análisis • Dec 08
Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects
With a price-to-earnings (or "P/E") ratio of 45.8x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...Actualización de narrativa • Dec 05
ALK B: Future Returns Will Reflect China Alliance And Margin Outlook
Analysts have maintained their DKK 219.33 price target for ALK Abelló, reflecting stable expectations for sustained double digit revenue growth, robust profit margins and a premium future P E multiple. What's in the News Upgraded 2025 guidance, with expected revenue growth raised to 13% to 15% in local currencies, supported by higher treatment volumes across allergy immunotherapy and anaphylaxis products, and an improved projected EBIT margin of about 26% (company guidance).Actualización de narrativa • Nov 21
ALK B: Improved Margins and China Partnership Will Drive Steady Outlook
Analysts have raised their price target for ALK-Abelló to DKK 219.33 from DKK 196.00. They cite ongoing improvements in profit margins and a slightly higher projected fair value as the reasons for the adjustment.Artículo de análisis • Nov 15
ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...Actualización de narrativa • Nov 04
ALK B: Chinese Partnership And Revenue Upside Will Drive Future Opportunities
Analysts have raised their price target for ALK-Abelló from DKK 193 to DKK 196. This change is based on slightly improved revenue growth estimates and valuation adjustments.Artículo de análisis • Oct 11
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Actualización de narrativa • Aug 23
Allergy+ Strategy Will Reach Millions With New Therapies
The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.
Nueva narrativa • Dec 11
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | DKK 1b |
| Dec 31 2025 | DKK 21m | DKK 8m | DKK 1b |
| Sep 30 2025 | n/a | n/a | DKK 1b |
| Jun 30 2025 | n/a | n/a | DKK 999m |
| Mar 31 2025 | n/a | n/a | DKK 937m |
| Dec 31 2024 | DKK 18m | DKK 7m | DKK 815m |
Compensación vs. Mercado: La compensación total ($USD3.18M) de Peter está en línea con el promedio de empresas de tamaño similar en el mercado Danish ($USD3.18M).
Compensación vs. Ingresos: La compensación de Peter ha sido consistente con los resultados de la empresa en el último año.
CEO
Peter Halling (49 yo)
3.6yrs
Permanencia
DKK 20,550,000
Compensación
Mr. Peter Halling is President & Chief Executive Officer of ALK-Abelló A/S from 2023 and serves as its Member of Management Board. Mr. Peter Halling served as Chief Executive Officer at Fertin Pharma A/S s...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 3.6yrs | DKK 20.55m | sin datos | |
| Executive VP | 3.2yrs | DKK 9.60m | sin datos | |
| Member of Management Board | 14.3yrs | DKK 13.27m | sin datos | |
| Senior Project Director | no data | DKK 400.00k | sin datos | |
| Senior Manager of QA Release & Employee Representative Director | no data | DKK 400.00k | sin datos | |
| Senior Maintenance Supporter of Process & Production Support & Employee Representative Director | no data | DKK 400.00k | sin datos | |
| Project Director of Global Clinical Development & Employee-elected Director | no data | DKK 400.00k | sin datos | |
| VP of Corporate Communications | no data | sin datos | sin datos | |
| Executive Vice President of Global People & Organisation | 2.6yrs | sin datos | sin datos | |
| Senior Vice President of Research & Development - North America and International Markets | 9.4yrs | sin datos | sin datos | |
| Executive Vice President of Product Supply | 7.6yrs | sin datos | sin datos | |
| Senior Vice President of Global Research & Drug Discovery | no data | sin datos | sin datos |
5.6yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALK B es experimentado (5.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Senior Project Director | 15.6yrs | DKK 400.00k | sin datos | |
| Senior Manager of QA Release & Employee Representative Director | 7.4yrs | DKK 400.00k | sin datos | |
| Senior Maintenance Supporter of Process & Production Support & Employee Representative Director | 7.4yrs | DKK 400.00k | sin datos | |
| Project Director of Global Clinical Development & Employee-elected Director | 3.4yrs | DKK 400.00k | sin datos | |
| Independent Director | 3.4yrs | DKK 540.00k | sin datos | |
| Vice Chairman of the Board | 12.6yrs | DKK 1.00m | sin datos | |
| Independent Chairman of the Board | 6.4yrs | DKK 1.45m | sin datos | |
| Director | 11.4yrs | DKK 540.00k | sin datos | |
| Independent Director | 5.4yrs | DKK 610.00k | sin datos | |
| Independent Director | 4.4yrs | DKK 650.00k | sin datos | |
| Independent Director | 5.4yrs | DKK 550.00k | sin datos |
6.4yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de ALK B se considera experimentada (6.4 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/18 15:17 |
| Precio de las acciones al final del día | 2026/08/18 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
ALK-Abelló A/S está cubierta por 9 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | ABG Sundal Collier |
| Mads Brinkmann Andersen | Berenberg |
| Jesper Ilsoe | Carnegie Investment Bank AB |